Cardiovascular Systems (NASDAQ: CSII) and VWR Corporation (NASDAQ:VWR) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.
This table compares Cardiovascular Systems and VWR Corporation’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation & Earnings
This table compares Cardiovascular Systems and VWR Corporation’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Cardiovascular Systems||$204.91 million||4.35||$5.43 million||($0.06)||-450.09|
|VWR Corporation||$4.58 billion||0.95||$492.10 million||$1.08||30.67|
VWR Corporation has higher revenue and earnings than Cardiovascular Systems. Cardiovascular Systems is trading at a lower price-to-earnings ratio than VWR Corporation, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
74.5% of Cardiovascular Systems shares are held by institutional investors. 3.3% of Cardiovascular Systems shares are held by insiders. Comparatively, 35.5% of VWR Corporation shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
This is a breakdown of recent recommendations and price targets for Cardiovascular Systems and VWR Corporation, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Cardiovascular Systems presently has a consensus price target of $34.25, suggesting a potential upside of 26.80%. VWR Corporation has a consensus price target of $29.00, suggesting a potential downside of 12.44%. Given Cardiovascular Systems’ stronger consensus rating and higher possible upside, research analysts clearly believe Cardiovascular Systems is more favorable than VWR Corporation.
Risk & Volatility
Cardiovascular Systems has a beta of 2.54, indicating that its share price is 154% more volatile than the S&P 500. Comparatively, VWR Corporation has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500.
Cardiovascular Systems beats VWR Corporation on 8 of the 15 factors compared between the two stocks.
Cardiovascular Systems Company Profile
Cardiovascular Systems, Inc. is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications. Its peripheral artery disease (PAD) systems are catheter-based platforms capable of treating a range of plaque types in leg arteries both above and below the knee. Its products include Diamondback 360 Peripheral Orbital Atherectomy System (OAS) (Diamondback 360 Peripheral), the Stealth 360 OAS (Stealth 360), Diamondback 360 Peripheral, Diamondback 360 60cm Peripheral, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral and Diamondback 360 2.00 Peripheral. The Company’s coronary arterial disease (CAD) product, Diamondback 360 Coronary OAS (Coronary OAS), is marketed as a treatment for severely calcified coronary arteries.
VWR Corporation Company Profile
VWR Corporation is a provider of product and service solutions to laboratory and production customers. The Company offers a portfolio of branded and private label laboratory products, services and solutions to the life science, general research and applied markets. The Company operates in two segments: Americas and EMEA-APAC. The Americas segment consists of operations located principally in the United States and Canada, as well as in Puerto Rico, Mexico and select countries in Central and South America, including Costa Rica, Brazil, Argentina and Chile. As of December 31, 2016, the Americas segment included 67 facilities located in eight countries. As of December 31, 2016, the EMEA-APAC segment consisted of its operations located principally in Europe, as well as in certain Asia-Pacific countries, and included 110 facilities located in 26 countries. The Company’s portfolio includes chemicals, reagents, consumables, durable products and scientific equipment and instruments.
What are top analysts saying about Cardiovascular Systems Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cardiovascular Systems Inc. and related companies.